



## **Crescendo Biologics to participate in upcoming investor and partnering conferences**

**Cambridge, UK, 29 February 2024** – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that members of the executive team will be participating at the following events.

- **Cowen Healthcare Conference, 4 - 6 March**
- **BIO-Europe Spring, 18-20 March**
- **Van Lanschot Kempen Life Sciences Conference, 16 - 17 April**
- **BioEquity Europe, 12 – 14 May**

The team looks forward to discussing the Company's business strategy, the latest updates on its lead programme, CB307 in prostate cancer, and the wider Humabody® VH oncology pipeline. To connect with the Company at or around these events, please email [investors@crescendobiologics.com](mailto:investors@crescendobiologics.com).

Please refer to the conference websites for further information and any updated schedules.

**-Ends-**

**For more information, please contact:**

### **Crescendo Biologics**

Theodora Harold, CEO  
+ 44 (0) 12 2349 7140  
[investors@crescendobiologics.com](mailto:investors@crescendobiologics.com)  
[media@crescendobiologics.com](mailto:media@crescendobiologics.com)

### **ICR Consilium**

Mary-Jane Elliott, David Daley, Sukaina Virji  
[crescendo@consilium-comms.com](mailto:crescendo@consilium-comms.com)

### **About CB307**

CB307 is Crescendo's lead clinical candidate, a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to deliver a safer and more durable anti-cancer T cell response.

CB307 conditionally activates only tumour-specific T cells, exclusively within the tumour microenvironment using the CD137 co-stimulatory mechanism. Its unique format enables potent, tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA+ cancer indications to address a large unmet medical need.

Clinical development of CB307 is on track with the Phase 1b POTENTIA trial ongoing in adult patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). POTENTIA ([NCT04839991](https://clinicaltrials.gov/ct2/show/study/NCT04839991)) is an open-label, dose escalation and cohort expansion study to assess the safety, tolerability and preliminary efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).



### **About Crescendo Biologics**

Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted T cell-enhancing therapeutics derived from its proprietary Humabody® V<sub>H</sub> platform. Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with Takeda and BioNTech, and an exclusive worldwide licensing agreement with Zai Lab. Located in Cambridge, UK, Crescendo is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital and Kreos Capital. Visit [www.crescendobiologics.com](http://www.crescendobiologics.com) and follow on [LinkedIn](#) and [X](#) (Twitter).